NovoCure Ltd — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NovoCure Ltd filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $655.35M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $605.22M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $509.34M | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | $128.43M | Feb 23, 2023 |
| FY2022 | Sep 30, 2022 | $131.00M | Feb 23, 2023 |
| FY2022 | Jun 30, 2022 | $140.87M | Feb 23, 2023 |
| FY2022 | Mar 31, 2022 | $137.55M | Feb 23, 2023 |
| FY2022 | Dec 31, 2021 | $133.21M | Feb 23, 2023 |
| FY2022 | Sep 30, 2021 | $133.61M | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | $133.52M | Feb 23, 2023 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $53.66M | Feb 22, 2018 |
| FY2017 | Sep 30, 2017 | $50.11M | Feb 22, 2018 |
| FY2017 | Jun 30, 2017 | $38.38M | Feb 22, 2018 |
| FY2017 | Mar 31, 2017 | $34.88M | Feb 22, 2018 |
| FY2017 | Dec 31, 2016 | $30.24M | Feb 22, 2018 |
| FY2017 | Sep 30, 2016 | $21.67M | Feb 22, 2018 |
| FY2017 | Jun 30, 2016 | $17.92M | Feb 22, 2018 |
| FY2017 | Mar 31, 2016 | $13.05M | Feb 22, 2018 |
| FY2016 | Dec 31, 2015 | $12.38M | Feb 23, 2017 |
| FY2016 | Sep 30, 2015 | $8.95M | Feb 23, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $488.47M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $468.04M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $381.06M | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | $99.54M | Feb 23, 2023 |
| FY2022 | Sep 30, 2022 | $101.25M | Feb 23, 2023 |
| FY2022 | Jun 30, 2022 | $112.36M | Feb 23, 2023 |
| FY2022 | Mar 31, 2022 | $109.82M | Feb 23, 2023 |
| FY2022 | Dec 31, 2021 | $103.53M | Feb 23, 2023 |
| FY2022 | Sep 30, 2021 | $103.40M | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | $104.92M | Feb 23, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($136.23M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($168.63M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($207.04M) | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | ($37.30M) | Feb 23, 2023 |
| FY2022 | Sep 30, 2022 | ($26.58M) | Feb 23, 2023 |
| FY2022 | Jun 30, 2022 | ($24.01M) | Feb 23, 2023 |
| FY2022 | Mar 31, 2022 | ($4.65M) | Feb 23, 2023 |
| FY2022 | Dec 31, 2021 | ($26.46M) | Feb 23, 2023 |
| FY2022 | Sep 30, 2021 | ($13.12M) | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | ($14.64M) | Feb 23, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($153.80M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($170.50M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($232.87M) | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | ($42.98M) | Feb 23, 2023 |
| FY2022 | Sep 30, 2022 | ($24.61M) | Feb 23, 2023 |
| FY2022 | Jun 30, 2022 | ($21.13M) | Feb 23, 2023 |
| FY2022 | Mar 31, 2022 | ($806.0K) | Feb 23, 2023 |
| FY2022 | Dec 31, 2021 | ($23.40M) | Feb 23, 2023 |
| FY2022 | Sep 30, 2021 | ($8.55M) | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | ($12.30M) | Feb 23, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $224.54M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $209.65M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $223.06M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $206.09M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $201.30M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $132.01M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $79.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $50.57M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $38.10M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $41.47M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($49.03M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($26.37M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($73.34M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $30.79M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $82.76M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $99.15M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $26.62M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($1.87M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($33.13M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($107.59M) | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.65M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $42.86M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $27.09M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $21.36M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $24.17M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $14.97M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $10.49M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $6.71M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $7.37M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $5.67M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $804.33M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.24B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.15B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.19B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $1.14B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $1.05B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $479.45M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $339.79M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $265.30M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $282.08M | Feb 22, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $463.86M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $880.61M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $783.63M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $750.48M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $729.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $575.46M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $261.66M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $227.53M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $151.73M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $139.74M | Feb 22, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $340.47M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $360.18M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $362.50M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $441.17M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $410.49M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $476.53M | Feb 22, 2024 |
| FY2022 | Dec 31, 2019 | $217.79M | Feb 23, 2023 |
| FY2021 | Dec 31, 2018 | $112.26M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $113.56M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $142.35M | Feb 27, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.29B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($1.15B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($985.50M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($778.46M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($685.93M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($631.08M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($650.89M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($643.66M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($582.26M) | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($519.93M) | Feb 22, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.55M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $163.77M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $240.82M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $115.33M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $208.80M | Feb 22, 2024 |
| FY2021 | Dec 31, 2020 | $234.67M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $177.32M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $140.62M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $78.59M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $99.78M | Feb 22, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $568.82M | Feb 22, 2024 |
| FY2023 | Dec 31, 2022 | $565.51M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $562.22M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $429.91M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $149.42M | Feb 25, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Feb 23, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Feb 23, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Feb 23, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Feb 23, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Feb 23, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Feb 23, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Feb 23, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Feb 23, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Feb 23, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Feb 23, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Feb 23, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Feb 23, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Feb 23, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 112.49M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 108.52M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 107.08M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 105.05M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 103.97M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 102.33M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 99.53M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 93.25M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 89.48M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 87.07M | Feb 22, 2018 |